Anika Therapeutics, Inc. (ANIK)
NASDAQ: ANIK · Real-Time Price · USD
14.96
+0.84 (5.95%)
Mar 9, 2026, 4:00 PM EDT - Market closed

Anika Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-10.88-56.39-82.67-14.864.13
Depreciation & Amortization
5.738.1214.2214.4920.78
Stock-Based Compensation
10.0813.1315.2414.3211.09
Other Adjustments
7.0853.6363.542.29-12.89
Change in Receivables
0.413.37-1.31-5.63-6.22
Changes in Inventories
0.03-9.42-11.4-6.87-6.62
Changes in Accounts Payable
0.04-2.51-0.011.97-1.1
Changes in Accrued Expenses
-1.5-3.671.65-0.443.51
Changes in Income Taxes Payable
-0.130.670.531.44-1.31
Changes in Other Operating Activities
0.33-1.52-1.59-2.28-2.98
Operating Cash Flow
11.195.4-1.794.418.4
Operating Cash Flow Growth
107.07%---47.49%-35.73%
Capital Expenditures
-6.83-7.73-5.43-7.49-5.14
Purchases of Intangible Assets
--0.6---
Proceeds from Sale of Intangible Assets
0.6----
Proceeds from Sale of Investments
----2.5
Payments for Business Acquisitions
-----0.48
Proceeds from Business Divestments
4.5----
Other Investing Activities
1.33----
Investing Cash Flow
-0.4-8.33-5.43-7.49-3.12
Issuance of Common Stock
0.50.780.830.681.13
Repurchase of Common Stock
-11.05-13.51-7.15-0.93-0.49
Net Common Stock Issued (Repurchased)
-10.55-12.73-6.32-0.250.64
Other Financing Activities
----4.6-7.42
Financing Cash Flow
-10.55-12.73-6.32-4.85-6.78
Effect of Exchange Rate Changes on Cash and Cash Equivalents
0.09-0.050.08-0.130.07
Net Cash Flow
0.32-15.71-13.46-8.06-1.43
Free Cash Flow
4.36-2.33-7.22-3.083.25
Free Cash Flow Growth
-----71.55%
FCF Margin
3.87%-1.94%-5.97%-2.70%2.20%
Free Cash Flow Per Share
0.30-0.16-0.49-0.210.22
Levered Free Cash Flow
-13.21-72.46-84.7-14.0511.27
Unlevered Free Cash Flow
-14.18-32.36-2.952.6811.59
Updated Feb 26, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q